FDA Issues Early Communication About an Ongoing Safety Review of
FDA Issues Early Communication About an Ongoing Safety Review of Aprotinin Injection
The U.S. Food and Drug Administration (FDA) issued an Early Communication about an Ongoing Safety Review of Aprotinin Injection (marketed as Trasylol), a drug used to control bleeding during heart surgery.